Writing on the wall' suggests progress in ALS may be imminent, says Cytokinetics CEO

22 August 2017

San Franciscan firm Cytokinetics (Nasdaq: CYTK) is pursuing an unusual angle to therapeutic discovery, starting from an understanding of the biology of muscles in order to explore treatment options in different disease areas.

This approach has seen the company develop a diverse pipeline of candidates, in heart failure, in spinal muscular atrophy (SMA) and in amyotrophic lateral sclerosis (ALS), where lead candidate tirasemtiv is due to read out at Phase III later this year.

Launched 20 years ago, chief executive Robert Blum was with the firm from the start, leading in R&D and ultimately taking the tiller a few years after they went public in 2004.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK